Identification of anti-inflammatory drugs according to their capacity to suppress type-1 and type-2 T cell profiles

Clinical and Experimental Allergy

Volumn 34, Issue 12, 2004, Pages 1868-1875

  Moed, H ^a   Stoof, T J ^a   Boorsma, D M ^a   Von Blomberg, B M E ^a   Gibbs, S ^a   Bruynzeel, D P ^a   Scheper, R J ^a   Rustemeyer, T ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allergic contact dermatitis; Anti inflammatory drugs; Chemokine receptor; Cytokine; Down regulation; T cell

Indexed keywords

ANTIINFLAMMATORY AGENT; CALCITRIOL; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; CYCLOSPORIN A; CYTOKINE; DICLOFENAC; FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON; GROWTH FACTOR; HYDROCORTISONE; INTERLEUKIN 2; INTERLEUKIN 5; LACTOFERRIN;

ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DNA SYNTHESIS; DRUG INHIBITION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; NICKEL HYPERSENSITIVITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN ALLERGY; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CHOLECALCIFEROL; CYCLOSPORINE; DERMATITIS, ALLERGIC CONTACT; DICLOFENAC; FLOW CYTOMETRY; FUMARATES; HUMANS; HYDROCORTISONE; INTERLEUKIN-12; INTERLEUKIN-4; INTERLEUKIN-7; LACTOFERRIN; LYMPHOCYTE ACTIVATION; NICKEL; PATCH TESTS; TH1 CELLS; TH2 CELLS;

EID: 11144325701     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02124.x     Document Type: Article

References (44)

1. Fleischer AB Jr. Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol 1999; 104:S126-30.
2. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30:977-81.
3. Haczku A, Alexander A, Brown P et al. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid- resistant chronic asthma. J Allergy Clin Immunol 1994; 93:510-9.
4. Granlund H, Erkko P, Reitamo S. Long-term follow-up of eczema patients treated with cyclosporine. Acta Derm Venereol 1998; 78:40-3.
5. Horroccks A, Ormerod AD, Duncan JI et al. Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions. Clin Exp Immunol 1989; 78:166-71.
6. Kira M, Kobayashi T, Yoshikawa K. Vitamin D and the skin. J Dermatol 2003; 30:429-37.
7. Nieboer C, de Hoop D, van Loenen AC et al. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989; 20:601-8.
8. Litjens NH, Nibbering PH, Barrois AJ et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003; 148: 444-51.
9. Ockenfels HM, Schultewolter T, Ockenfels G et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139:390-5.
10. Griffiths CE, Cumberbatch M, Tucker SC et al. Exogenous topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. Br J Dermatol 2001; 144: 715-25.
11. Fessler BJ, Paliogianni F, Hama N et al. Glucocorticoids modulate CD28 mediated pathways for interleukin 2 production in human T cells: evidence for posttranscriptional regulation. Transplantation 1996; 62:1113-8.
12. Baus E, Andris F, Dubois PM et al. Dexamethasone inhibits the early steps of antigen receptor signaling in activated T lymphocytes. J Immunol 1996; 156:4555-61.
13. Bianchi M, Meng C, Ivashkiv LB. Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids. Proc Natl Acad Sci USA 2000; 97:9573-8.
14. Rustemeyer T, van Hoogstraten IMW, von Blomberg BME et al. Mechanisms in allergic contact dermatitis. Textbook of contact dermatitis, 3rd Ed. Berlin: Springer Verlag, 2001.
15. + and express the chemokine receptors CXCR3, CCR4 and CCR10. Br J Dermatol 2004; 151:32-41.
16. + T cells. J Invest Dermatol 1998; 111:621-8.
17. Sinigaglia F, Scheidegger D, Garotta G et al. Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis. J Immunol 1985; 135:3929-32.
18. Homey B, Alenius H, Muller A et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-65.
19. Reiss Y, Proudfoot AE, Power CA et al. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001; 194:1541-7.
20. Flier J, Boorsma DM, Bruynzeel DP et al. The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol 1999; 113:574-8.
21. Sebastiani S, Albanesi C, Nasorri F et al. Nickel-specific CD4(+) and CD8(+) T cells display distinct migratory responses to chemokines produced during allergic contact dermatitis. J Invest Dermatol 2002; 118:1052-8.
22. Rustemeyer T, von Blomberg BM, van Hoogstraten IMW et al. Analysis of effector and regulatory immune reactivity to nickel. Clin Exp Allergy 2004; 34:1458-66.
23. Hamawy MM. Molecular actions of calcineurin inhibitors. Drug News Perspect 2003; 16:277-82.
24. Singh S, Aiba S, Manome H et al. The effects of dexamethasone, cyclosporine, and vitamin D(3) on the activation of dendritic cells stimulated by haptens. Arch Dermatol Res 1999; 291:548-54.
25. Dhennin-Duthille I, Masson M, Damiens E et al. Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. J Cell Biochem 2000; 79:583-93.
26. Moriuchi M, Moriuchi H. A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J Immunol 2001; 166:4231-6.
27. Cumberbatch M, Bhushan M, Dearman RJ et al. IL-1 beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol 2003; 132:352-9.
28. Cumberbatch M, Dearman RJ, Uribe-Luna S et al. Regulation of epidermal Langerhans cell migration by lactoferrin. Immunology 2000; 100:21-8.
29. Zimecki M, Mazurier J, Spik G et al. Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch Immunol Ther Exp 1996; 44:51-6.
30. Mincheva-Nilsson L, Hammarstrom S, Hammarstrom ML. Activated human gamma delta T lymphocytes express functional lactoferrin receptors. Scand J Immunol 1997; 46:609-18.
31. Boonstra A, Barrat FJ, Crain C et al. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167:4974-80.
32. Lemire JM. Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 1995; 53:599-602.
33. D'Ambrosio D, Cippitelli M, Cocciolo MG et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB down regulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101:252-62.
34. Piemonti L, Monti P, Sironi M et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164:4443-51.
35. Brinkmann V, Kristofic C. Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD. J Immunol 1995; 155:3322-8.
36. Agarwal SK, Marshall GD Jr. Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines. J Interferon Cytokine Res 2001; 21:147-55.
37. Braun CM, Huang SK, Bashian GG et al. Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J Allergy Clin Immunol 1997; 100:400-7.
38. Snijdewint FG, Kapsenberg ML, Wauben-Penris PJ et al. Corticosteroids class-dependently inhibit in vitro Th1- and Th2-type cytokine production. Immunopharmacology 1995; 29: 93-101.
39. Umland SP, Nahrebne DK, Razac S et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997; 100:511-9.
40. Stoof TJ, Flier J, Sampat S et al. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001; 144:1114-20.
41. de Jong R, Bezemer AC, Zomerdijk TP et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26:2067-74.
42. Tsuboi I, Tanaka H, Nakao M et al. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Cytokine 1995; 7:372-9.
43. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002; 46:886-91.
44. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-90.